ArticleProtoplasma2012
Role of bacterioferritin comigratory protein and glutathione peroxidase-reductase system in promoting bentazone tolerance in a mutant of Synechococcus elongatus PCC7942.
Article in Protoplasma, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 9 citations in OpenAlex.
- Elevated carbon dioxide levels lead to proteome-wide alterations for optimal growth of a fast-growing cyanobacterium, Synechococcus elongatus PCC 11801.Scientific reports · 2019Article
- Integrated OMICS guided engineering of biofuel butanol-tolerance in photosynthetic Synechocystis sp. PCC 6803.Biotechnology for biofuels · 2013Article
- RNA-seq based identification and mutant validation of gene targets related to ethanol resistance in cyanobacterial Synechocystis sp. PCC 6803.Biotechnology for biofuels · 2012Article
- A bentazone-resistant mutant of cyanobacterium, Synechococcus elongatus PCC7942 adapts different strategies to counteract on bromoxynil- and salt-mediated oxidative stress.Physiology and molecular biology of plants : an international journal of functional plant biology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this article, we describe the modifications in the antioxidant system of Synechococcus elongatus PCC7942 mutant Mu2 capable of growing at five times higher concentration of bentazone than wild type. Nevertheless, in both the strains, bentazone almost identically induced light-dependent H(2)O(2) production and its extracellular release. However unlike the wild type, peroxide produced upon prolong bentazone incubation was immediately degraded in Mu2. Consequently, the lipid peroxidation activity was also kept low. With prolong incubation of bentazone the mutant displayed a steady increase in glutathione peroxidase-reductase enzyme activities and reduced glutathione content, respectively, by 60% and 130%, favoring an efficient detoxification of bentazone-produced H(2)O(2). Catalase-peroxidase and glutathione S-transferase, though present, remained ineffective in rendering bentazone tolerance. In-gel assays of glutathione S-transferase and glutathione reductase revealed presence of between four and five oligomeric states with mobility shifts. One oligomeric form each enzyme in wild-type strain disappeared upon bentazone treatment. Upon two-dimensional electrophoresis and MALDI-TOF/TOF, a bacterioferritin comigratory protein (peroxiredoxin Q) was found to be already highly expressed in Mu2; whereas in wild type, its level increased only upon bentazone exposure. The bcp transcript pool in WT was relatively low but increased with bentazone, whereas Mu2 exhibited high bcp mRNA even without herbicide. Bacterioferritin comigratory protein and glutathione peroxidase-reductase appear to be responsible for detoxification of bentazone-derived peroxide in Mu2.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.